Valizadeh Nasim, Nateghi Shahin, Noroozi Mehran, Hejazi Sasan, Aghanezhad Fateme, Ali Afsaneh Akbarpoor Morad
Department of Hematology & Medical Oncology, Emam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.
Asian J Transfus Sci. 2013 Jan;7(1):55-8. doi: 10.4103/0973-6247.106739.
Although, in the past the risk of transfusion transmitted viral infections were high in hemophilia patients, but introduction of viral inactivation methods in1985,decreased the risk of human immunodeficiency and hepatitis C and B viruses transmission significantly. The aim of study was seroprevalence of hepatitis B surface antigen (HBs Ag), hepatitis C virus antibody (HCV Ab) and human immunodeficiency virus antibody (HIVAb) in hemophiliacs in west Azarbaijan of Iran, born in 1985-2010.
In a cross-sectional study, fifty patients with hereditary bleeding disorders born in 1985-2010, from total 250 patients who had been registered in Urmia Hemophilia Society were enrolled through the year 2010 to assess their seroprevalence for HCV Ab, HIV Ab and HBs Ag. Thirty five of 50 patients had hemophilia. Also; we performed a subset analysis for hemophilia patients.
All 50 patients with hereditary bleeding disorders including 35 patients with hemophilia were seronegative for HIV Ab and HBs Ag. HCV-Ab was detected in serum of 3 of 50 (6%) patients with bleeding disorders. After subset analysis for hemophilia (A and B) patients, we found HCV infection in 8.57% (3 of 35) of hemophiliacs.
In this study prevalence of HCV infection was very smaller than similar studies in Iran and other countries. This study shows the safety of using viral inactivated factor concentrates and recombinant factors after year 1985. None of Hemophiliacs were seropositive for HIV Ab and HBs Ag.
尽管过去血友病患者经输血传播病毒感染的风险很高,但1985年引入病毒灭活方法后,显著降低了人类免疫缺陷病毒以及丙型和乙型肝炎病毒的传播风险。本研究的目的是调查1985年至2010年出生在伊朗西阿塞拜疆省的血友病患者中乙型肝炎表面抗原(HBs Ag)、丙型肝炎病毒抗体(HCV Ab)和人类免疫缺陷病毒抗体(HIVAb)的血清流行率。
在一项横断面研究中,从乌尔米血友病协会登记的250名患者中,纳入了50名1985年至2010年出生的遗传性出血性疾病患者,在2010年全年对他们进行HCV Ab、HIV Ab和HBs Ag血清流行率评估。50名患者中有35名患有血友病。此外,我们对血友病患者进行了亚组分析。
所有50名遗传性出血性疾病患者,包括35名血友病患者,HIV Ab和HBs Ag血清学检测均为阴性。50名出血性疾病患者中有3名(6%)血清检测出HCV-Ab。对血友病(A和B)患者进行亚组分析后,我们发现8.57%(35名中的3名)的血友病患者感染了HCV。
在本研究中,HCV感染的流行率远低于伊朗和其他国家的类似研究。本研究表明1985年后使用病毒灭活因子浓缩物和重组因子是安全的。血友病患者中没有HIV Ab和HBs Ag血清学阳性者。